Healthcare Leaders Slam Exclusion of Key Healthcare Provisions in Spending Package
Several healthcare provisions, including drug reforms, were left out of the government funding bill, angering some healthcare leaders.
Several healthcare provisions, including drug reforms, were left out of the government funding bill, angering some healthcare leaders.
Congress released a stopgap funding bill with a significant healthcare package, and provider groups are reacting favorably. They are mainly applauding provisions that reign in PBMs’ business practices, extend telehealth flexibilities, and boost payments to hospitals and physicians.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
In a letter, Families USA and numerous other organizations called on Congress to extend the enhanced premium tax credits that are set to expire at the end of 2025.
In two letters, U.S. representatives and senators called for an extension of the enhanced premium tax credits, which are set to expire in 2025 and have lowered costs for those purchasing coverage on the marketplace.
More than 330 provider organizations signed letters this week urging the White House and Congress to extend a pandemic-era telehealth prescribing flexibility. Failure to extend this policy would cause millions of Americans to lose access to treatment, they argued.
Telehealth advocates are calling on Congress to act quickly on Medicare telehealth flexibilities, which are set to expire at the end of the year. Doing so would help key healthcare stakeholders prepare.
This bipartisan legislation will help create a more transparent process that allows patients and physicians to seek exceptions to step therapy protocol. Although it only applies to employer-sponsored health plans, the bill represents an important step towards reining in this troubling practice.
An AHIP survey found that 73% of commercially-insured telehealth users think that Congress should make telehealth provisions permanent. These provisions were put in place to meet Americans' needs during Covid-19.
The law enacted by Congress in 2008, aims to remove insurance-related obstacles to mental health and substance use disorder treatment, but it hasn't been enforced effectively and there is a lack of oversight.
Drug prices are on the minds of patients and politicians. The November election is expected to tip the balance of power in Congress and a panel held during the Biotechnology Innovation Organization’s annual meeting discussed what that change could mean for drug price legislation.
Providers, health systems and patient groups who want to see telehealth survive beyond the federal public health emergency need to engage their lawmakers and associations now to demonstrate the need and utility for continued telemedicine.
Congress will have to debate whether pandemic era telehealth reimbursement and relaxation of rules should be made permanent. Given that those rules helped historically underserved populations access care as well as those seeking mental health services, experts believe there's too much to lose to simply go back to the old ways.
In an unusual move, the Food and Drug Administration issued an alert about false negatives in startup Curative’s Covid-19 test. The test was being used by the County of Los Angeles, as well as Congress.
Congress finally reached an agreement on a $900 billion stimulus package, which includes a ban on surprise medical billing. A previous, but very similar version of the bill, raised concerns among providers and payers.
Congressional Democrats and Republicans introduced privacy bills that attempt to rein in what companies can do with data collected during the Covid-19 pandemic.